Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 6Active not recruiting 3Completed 2Terminated 1Suspended 1Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Neoplasms 6Glioblastoma 6Colorectal Neoplasms 6Breast Neoplasms 6Neoplasm Metastasis 5Prostatic Neoplasms 4Pancreatic Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Multiple Myeloma 3Leukemia, Myeloid, Acute 3Glioma 3Carcinoma, Hepatocellular 3Triple Negative Breast Neoplasms 2Solid Tumors 2Solid Tumor 2Sarcoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Osteosarcoma 2Melanoma 2Lymphoma, T-Cell 2Lung Neoplasms 2Immunoblastic Lymphadenopathy 2Carcinoma, Renal Cell 2Carcinoma 2Brain Neoplasms 2Biliary Tract Neoplasms 2Astrocytoma 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1

Interventions

TAK-243 1Specimen Handling 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Anemia, Refractory, with Excess of Blasts × 30 days × Clear all
NCT03816319 2026-05-18

TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts

National Cancer Institute (NCI)

Phase 1 Suspended
42 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡